tbuckley/cabot-search huggingface dataset:
Do clinical trial acronyms affect patients’ interest in clinical trials? A randomized survey.
Authors: Meagan Wiebe, Liying Zhang, Gillian Spiegle, Yoo-Joung Ko
Journal: Journal of Clinical Oncology (2013)

6639 Background: The use of acronyms in naming clinical trials has increased in recent years with minimal empirical examination of the effect that they have on research participants. The naming of trials is often a symbolic act; however, they may have a provocative origin that stimulates associations and influences perceptions of the research. No empirical evidence exists to confirm the supposition that certain trial acronyms may be coercive. The purpose of this study was to determine if a clinical trial title has an influence on a subject’s interest in a fictitious clinical trial. Methods: Two fictitious clinical trial scenarios (prevention and metastatic) for colon cancer were designed with the same three acronym titles (“CURE” a coercive, “RESCUE” a potentially coercive, and “COMET” a neutral acronym). An anonymous paper survey was randomly distributed to patients and caregivers at a comprehensive cancer center over a four-week period. Six different surveys were distributed and self-administered. Participants rated their interest in the clinical trial on a 5-point Likert scale and demographic information was collected. To determine the influence of acronym type on the Likert scale, univariate and multivariate ordinal logistic regression analysis was performed. Results: A response rate of 77.19% (1056/1368) was achieved. The specific acronym type (coercive and potentially coercive versus neutral) had no significant influence on the respondent’s interest in the clinical trial in either the preventive (p=0.787, OR=0.95) or the metastatic (p=0.284, OR=1.21) scenario. Only current (p=0.025, OR=1.56) or prior (p=0.038, OR=1.43) participation in a clinical trial positively influenced respondent’s interest in the fictitious clinical trials irrespective of the acronym title. Conclusions: Acronyms are commonly used in naming clinical trials and may facilitate clinician recall and familiarity. Although trial names may be perceived as potentially coercive, the results from this study suggest that coercive or potentially coercive acronym titles do not appear to influence patients’ or caregivers’ interest in the clinical trial.
Incorporating Metrics of Surgical Proficiency Into Credentialing and Privileging Pathways
Authors: Vernissia Tam, Herbert J. Zeh, Melissa E. Hogg
Journal: JAMA Surgery (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Thrombin Generation Test, F1+2 and TAT Levels in Hemophiliacs.
Authors: Pantelis P.E. Makris, Grigoris G.T. Gerotziafas, Fotis F.I. Girtovitis, George G.I. Ioannidis, Michell M.P. Makris, Elefteria E. Pithara, Michell M.M. Samama
Journal: Blood (2005)
Carfilzomib, An Irreversible Proteasome Inhibitor, Induces Long-Term Growth Inhibition of Mantle Cell Lymphoma In Vivo,
Authors: Liang Zhang, Jianfei Qian, Zhishuo Ou, Luhong Sun, Kejie Zhang, Lan V Pham, Christopher J Kirk, Richard J. Ford, Qing Yi, Michael Wang
Journal: Blood (2011)
Benefit of Consolidative Autologous Stem Cell Transplantation in First Complete Remission for Patients with Double Hit Lymphoma Appears Dependent on Induction Regimen Intensity
Authors: Daniel J. Landsburg, Nishitha Reddy, Christina Howlett, Tatyana Feldman, Anthony R. Mato, Jason B Kaplan, Amir Behdad, Adam M. Petrich, Joseph Maly, Kristie Blum, Julio C. Chavez, Shaoying Li, L. Jeffrey Medeiros, Marissa K. Falkiewicz, Brian T. Hill, Arun Singavi, Timothy S. Fenske, James Gerson, Stefan Klaus Barta, Pallawi Torka, Francisco J. Hernandez-Ilizaliturri, Cristiana A Costa, Frederick Lansigan, Oscar Calzada, Jonathon B. Cohen, Jennifer Kimberly Lue, Jennifer E Amengual, Xavier Rivera, Daniel Oscar Persky, David Peace, Ryan D Cassaday
Journal: Blood (2016)
Bertolotti Syndrome Demonstrated on 18F-NaF PET/CT
Authors: Sharjeel Usmani, Najeeb Ahmed, Fahad Marafi, Fareeda Al Kandari
Journal: Clinical Nuclear Medicine (2017)

Bertolotti syndrome is a form of low-back pain associated with lumbosacral transitional vertebrae. We report a case of a 34-year-old woman with breast cancer presented with severe low-back pain. 18F-NaF PET/CT demonstrates increased radiotracer uptake at the transverse-sacral articulation corresponding to hemisacralized left transverse process of L5 vertebra. Increased tracer uptake in patients with lumbosacral transitional vertebrae seems to correlate with lower-back pain symptoms. 18F-NaF PET/CT can be useful in evaluation of some uncommon causes of low-back pain. Bertolotti syndrome should always be included in the differential diagnosis of lower-back pain in young patients.
Determination of locally advanced basal cell carcinoma (BCC) in the first 285 patients enrolled in the RegiSONIC disease registry study.
Authors: Simon S. Yoo, Jean Y. Tang, Gary S. Rogers, Thomas Olencki, Mario E. Lacouture, Ragini Reiney Kudchadkar, Julie Guillen, Yong Mun, Keith Lamont Dawson, Aleksandar Sekulic
Journal: Journal of Clinical Oncology (2015)

9022 Background: Advanced BCC (aBCC), including metastatic (mBCC) or locally advanced BCC (laBCC), is rare, and a broadly accepted diagnostic definition of aBCC is lacking. The RegiSONIC disease registry (ClinicalTrials.gov identifier: NCT01604252) is designed to evaluate how clinicians diagnose and treat aBCC in real-world practice. Methods: RegiSONIC is an ongoing, multicenter, prospective observational cohort study in 3 BCC patient (pt) populations, treated according to clinician’s standard of care: newly diagnosed pts with vismodegib-naive aBCC (cohort 1), pts with aBCC who previously received vismodegib in a Genentech-sponsored study (cohort 2), or pts with BCCNS who have aBCC or multiple BCCs of any stage (cohort 3). Determination of aBCC was at the clinician’s discretion and not dictated by the protocol. This summary describes determination of laBCC in the first 285 pts enrolled to cohort 1 as of September 12, 2014. Results: Median time from initial diagnosis of the current BCC lesion to enrollment was 1.64 months and from determination of laBCC to enrollment was 0.43 months. Determination of laBCC was based on the following (sums to > 100%): lesion size (78%), histopathology (55%), location (53%), extent of disease (51%), recurrence (30%), curative resection unlikely (29%), radiotherapy contraindicated (21%), surgery contraindicated (16%), and other (8%). All pts had clinically visible locally advanced lesions; 72% had a single lesion, and 28% had multiple lesions (median, 3.0 lesions). The median size of target lesions was 20 mm; among 220 pts diagnosed on the basis of lesion size, 65% had lesions measuring ≥ 20 mm. Among 84 pts diagnosed on the basis of recurrence, 40% had ≥ 2 recurrences. Clinical/histopathologic subtype of the target lesion (sums to > 100%) was nodular (64%), morpheiform/infiltrative (29%), superficial (13%), micronodular (3%), basosquamous (3%), and other (11%). Target lesions were predominantly located on the head, including the nose (22.4%), forehead (12.6%), ear (8.3%), cheek (8.3%), and scalp (7.6%). Conclusions: Data from RegiSONIC will provide real-world clinical practice insight to help improve the diagnosis and care of pts with aBCC. Clinical trial information: NCT01604252.
Multiple Injuries in Blunt Abdominal Trauma
Authors: Sunu Philip, Gamal Mostafa, Dimitrios Apostolou
Journal: JAMA Surgery (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Abstract P5-16-25: Serum 25-hydroxyvitamin D levels and oncologic outcomes of breast cancer patients receiving neoadjuvant chemotherapy
Authors: S Park, JS Lee, JH Kim, SM Lim, HS Park, SI Kim
Journal: Cancer Research (2017)

Abstract Background:According to prior studies, the role of serum vitamin D3 has been inconsistentand clinical implications of 25-hyrdoxyvitamin D (25-OHD) have been little studiedin breast cancer patients receiving neoadjuvant chemotherapy (NCT). Objectives: The aims of study were to investigate changes in 25-OHD levels before and after NCT and to determine the association of 25-OHD and oncologic outcomes including pathological complete response (pCR) in breast cancer patients. Patients and Materials: From January 2010 to December 2013, serum 25-OHD levels at pre- and post-NCT were measured in 377 breast cancer patients. The association of serum 25-OHD levels with clinicopathological data including breast cancer subtypes, pCR and survival were retrospectively analysed. Delta 25-OHD was calculated as serum 25-OHDlevels before minus after NCT. Results: Mean ageof study population was 48.7 yearsand mean follow-up periods were 35.9months.Mean baseline serum 25-OHD concentration was 14.60 ng/mL (standard deviation, 7.44) and more than 80% of patients showed insufficient 25-OHD levels. The mean 25-OHDat post-NCT was 12.16 ng/mL (standard deviation, 6.87).There was a significant decrease in serum 25-OHD after NACT (p&amp;lt;0.001).The pCR rates were 25.7% among study cohort.However, 25-OHD levels at baseline and post-NCT were not related to pCR and survival outcomes. No associations were found between pCR and delta 25-OHD. According to stratification by breast cancer subtypes, however, patients with ≥ -2.67 (median value) of delta 25-OHD revealed a trend of higher achievement of pCR and better survival in luminal A subtype. No associations were found among the other subtypes. Conclusions: Many Korean breast cancer patients showed insufficient serum 25-OHD levels at diagnosis of malignancy and a significant decrease in serum vitamin D3 after NACT was observed.No significant association of 25-OHD 3 with pCR and survival was found. Therefore, correction or maintenance of appropriate serum 25-OHD levels should be focused for bone health as comprehensive management of breast cancer during NCT.In addition, possible oncological aspects of 25-OHD should further researched individually considering breast subtypes. Citation Format: Park S, Lee JS, Kim JH, Lim SM, Park HS, Kim SI. Serum 25-hydroxyvitamin D levels and oncologic outcomes of breast cancer patients receiving neoadjuvant chemotherapy [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P5-16-25.
In Vivo Screening for Tumor Suppressors In Hematological Malignancies Using Barcode RNAi
Authors: Roland Jäger, Markus Muellner, Florian Grebien, Thorsten Klampfl, Ashot Harutyunyan, Damla Olcaydu, Tiina Berg, Sebastian Nijman, Robert Kralovics
Journal: Blood (2010)
Glutamine Dipeptide Enriched Parenteral Nutrition Significantly Increase Short-Term Survival after HLA-Identical Allogeneic Stem Cell Transplantation.
Authors: Henrique O.G. Torres, Eduardo G. Vilela, Aloisio S. Cunha, Eugenio M.A. Goulart, Marcelo H.C. Souza, Ana Carolina C. Aguirre, Wellington M. Azevedo, Fernanda M. Lodi, Henrique N.S. Bittencourt
Journal: Blood (2006)
Abstract P3-04-27: Delineating novel molecular pathways driving endocrine resistance in breast cancer
Authors: A Bosch, J Staaf, N Akrap, KK Kaminska, S Borgquist, Å Borg, G Honeth
Journal: Cancer Research (2017)

Abstract Background Estrogen receptor (ER) is a main driver of tumor progression in ER+ metastatic breast cancer (MBC). The use of endocrine therapy can effectively control the disease in a large proportion of patients. However, the majority of MBC eventually become resistant and progress. To elucidate the mechanisms of acquired resistance to endocrine treatment is key in order to better select therapeutic partners and delay disease progression. Methods A panel of ER+ breast cancer cell lines initially sensitive to the selective estrogen receptor degrader (SERD) fulvestrant was exposed to increasing concentrations of this drug over several months to induce resistance. Cell proliferation was determined with the xCELLigence system. Protein expression was measured by phospho-kinase array and western blotting. RNA expression was evaluated by gene expression microarray analysis (Illumina) and validated by RT-qPCR. Cell cycle distribution was analyzed by flow cytometry. Results Using an unbiased approach to identify pathways that drive endocrine resistance, both the parental and the resistant cell models were studied. As expected, fulvestrant treatment resulted in G1-cell cycle arrest in the parental cell lines. In stark contrast, resistant cells bypassed fulvestrant-induced proliferation block despite a lower expression of genes driving mitotic progression compared to untreated parental cells. This gene expression pattern was coupled with a reduction of ER protein level in the resistant cells, which was in line with a significant decrease in the expression of ER-target genes. Our phospho-screen analysis showed a genotype specific down-modulation of p53 and up-regulation of several signaling components of mitogenic pathways in resistant cells compared to parental cells. Conclusions Our results suggest that acquired endocrine resistance is driven by multiple cell-specific mechanisms rather than a common molecular underpinning. Strikingly, there is one unique feature in our models, which is a cellular switch towards an ER-independent gene expression program. Ongoing in vitro and in vivo studies, aimed at further characterizing these cellular models, will provide valuable insights into the heterogeneity underlying the response to endocrine treatment observed in MBC patients. Citation Format: Bosch A, Staaf J, Akrap N, Kaminska KK, Borgquist S, Borg Å, Honeth G. Delineating novel molecular pathways driving endocrine resistance in breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P3-04-27.
Once-Weekly Carfilzomib with Dexamethasone Demonstrated Promising Safety and Efficacy in Patients with Relapsed or Refractory Multiple Myeloma Regardless of Age and Prior Bortezomib Exposure
Authors: Jesus G. Berdeja, Robert M. Rifkin, Roger Lyons, Hui Yang, Anita Zahlten-Kuemeli, Sanjay K. Aggarwal, Karim Iskander, James Berenson
Journal: Blood (2016)
Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Primary End Point Analysis of the Phase 2 Keynote-087 Study
Authors: Craig H. Moskowitz, Pier Luigi Zinzani, Michelle A. Fanale, Philippe Armand, Nathalie A. Johnson, John A. Radford, Vincent Ribrag, Daniel Molin, Theodoros P. Vassilakopoulos, Akihiro Tomita, Bastian von Tresckow, Margaret A. Shipp, Eric Gustafson, Yinghua Zhang, Alejandro Daniel Ricart, Arun Balakumaran, Robert W Chen
Journal: Blood (2016)
Increase in Human Infections with Avian Influenza A(H7N9) Virus During the Fifth Epidemic — China, October 2016–February 2017
Authors: A. Danielle Iuliano, Yunho Jang, Joyce Jones, C. Todd Davis, David E. Wentworth, Timothy M. Uyeki, Katherine Roguski, Mark G. Thompson, Larisa Gubareva, Alicia M. Fry, Erin Burns, Susan Trock, Suizan Zhou, Jacqueline M. Katz, Daniel B. Jernigan
Journal: MMWR Morbidity and Mortality Weekly Report (2017)

During March 2013-February 24, 2017, annual epidemics of avian influenza A(H7N9) in China resulted in 1,258 avian influenza A(H7N9) virus infections in humans being reported to the World Health Organization (WHO) by the National Health and Family Planning Commission of China and other regional sources (1). During the first four epidemics, 88% of patients developed pneumonia, 68% were admitted to an intensive care unit, and 41% died (2). Candidate vaccine viruses (CVVs) were developed, and vaccine was manufactured based on representative viruses detected after the emergence of A(H7N9) virus in humans in 2013. During the ongoing fifth epidemic (beginning October 1, 2016),* 460 human infections with A(H7N9) virus have been reported, including 453 in mainland China, six associated with travel to mainland China from Hong Kong (four cases), Macao (one) and Taiwan (one), and one in an asymptomatic poultry worker in Macao (1). Although the clinical characteristics and risk factors for human infections do not appear to have changed (2,3), the reported human infections during the fifth epidemic represent a significant increase compared with the first four epidemics, which resulted in 135 (first epidemic), 320 (second), 226 (third), and 119 (fourth epidemic) human infections (2). Most human infections continue to result in severe respiratory illness and have been associated with poultry exposure. Although some limited human-to-human spread continues to be identified, no sustained human-to-human A(H7N9) transmission has been observed (2,3).
Analysis of the Phase 1a/b Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients with AL Amyloidosis
Authors: Camille V Edwards, Julia Gould, Arielle L Langer, Markus Mapara, Jai Radhakrishnan, Matthew S Maurer, Shahzad Raza, John G Mears, Jonathan S Wall, Alan Solomon, Suzanne Lentzsch
Journal: Blood (2016)
Changes in Percutaneous Coronary Interventions Deemed “Inappropriate” by Appropriate Use Criteria
Authors: Edward L. Hannan, Zaza Samadashvili, Kimberly Cozzens, Foster Gesten, Alda Osinaga, Douglas G. Fish, Constance L. Donahue, Ronald J. Bass, Gary Walford, Alice K. Jacobs, Ferdinand J. Venditti, Nicholas J. Stamato, Peter B. Berger, Samin Sharma, Spencer B. King
Journal: Journal of the American College of Cardiology (2017)
Increased Tonic PI3K Signaling Through p110α Can Limit the Efficacy of P110δ-Selective Inhibition in Mantle Cell Lymphoma, Particularly with Multiple Relapse
Authors: Sunil Iyengar, Andrew James Clear, Csaba Bödör, Lenushka Maharaj, Janet Matthews, Rebecca Auer, Sameena Iqbal, John G Gribben, Simon Joel
Journal: Blood (2012)
A Woman in Her 40s With Headache and New-Onset Seizures
Authors: Maya S. Graham, Anita Pudusseri, Jeffrey Helgager, Derek P. Narendra, Umberto De Girolami, Geraldine S. Pinkus, Vaishali Sanchorawala, Edison Miyawaki
Journal: JAMA Neurology (2017)

A woman in her 40s with a history of plasma cell leukemia presented with 1 month of intermittent headaches followed by a seizure. Results from laboratory studies were notable for a cerebrospinal fluid opening pressure of 28 mm H2O and 8 white blood cells, including 1 atypical plasma cell. Imaging studies revealed confluent bifrontal white matter fluid-attenuated inversion recovery hyperintensities, as well as a contrast-enhancing sellar lesion. The patient underwent a stereotactic biopsy. The differential diagnosis, pathologic findings, and diagnosis are discussed.
Effect of intercalated erlotinib with gemcitabine/cisplatin as neoadjuvant treatment in stage IIIA unrectable non-small cell lung cancer (CTONG 1101, NCT01297101) on disease-free survival: A single arm, multi-center, phase II study.
Authors: Chen Zhiwei, Jiang Gening, Wang Xin, Qingquan Luo, Shun Lu
Journal: Journal of Clinical Oncology (2015)

e18519 Background: The optimal treatment for locally advanced stage IIIA non-small cell lung cancer (NSCLC) disease is not well established yet although neoadjuvant chemotherapy showed active results in stage IIIA N2 pts. A few cases also indicate the advantages of neoadjuvant erlotinib. FASTACT II study showed that the regimen of erlotinib intercalated with chemotherapy improved PFS and OS in an unselected advanced NSCLC population of east Asian patients. Here we report the disease-free survival (DFS) results of a phase II study which was to assess the efficacy and safety profile of intercalated erlotinib with gemcitabine/cisplatin as neoadjuvant treatment in stage IIIA N2 NSCLC pts. Methods: Patients with untreated stage IIIA unresectable bulky N2 NSCLC and ECOG PS 0/1 were enrolled to receive up to 2 cycles of gemcitabine 1,000 mg/m2 on days 1 and 8 and cisplatin 75 mg/m2 on day 1 or carboplatin AUC = 5 d1, followed by oral erlotinib (150 mg, once a day) on days 15 to 28 as neoadjuvant therapy. A repeat computed tomography (CT) scan evaluated the response after induction therapy and eligible patients would undergo surgical resection. Results: Twenty-two (56.4%, median age 57.0 yrs) out of the enrolled 39 patients received surgical resection. Majority of pts (77.3%, 17/22) received adjuvant chemotherapy, and one received radiotherapy while four received non post-surgery treatment. Fifteen pts (68.2%, 15/22, 11male/4femal) had radical (R0) resection, in which 6 were EGFR mutant, 5 wild-type and 4 unknown, and 7 pts received R1/R2 resection. Till Jan 15,2015, the median follow up duration for R0 resection from the surgery date was 25.7(range: 7.3, 39.8) mo. Forty percent pts (6/15) had recurrence and already died after the surgery, 3 EGFR mut, 2 wild-type and 1 unknown. The median recurrent time was 4.0 (1.2, 15.6) mo for these 6 pts. The median DFS for R0 resection is not mature yet. Conclusions: Neoadjuvant erlotinib intercalated with gemcitabine/cisplatin brought clinical benefits by extending disease free survival for stage IIIA N2 NSCLC pts. It still needs further study. Clinical trial information: NCT01297101.
Inhibition of Chronic Myeloid Leukemia Stem Cells by the Combination of the Hedgehog Pathway Inhibitor LDE225 with Nilotinib
Authors: Bin Zhang, David Irvine, Yin Wei Ho, Silvia Buonamici, Paul Manley, Tessa L. Holyoake, Mhairi Copland, Ravi Bhatia
Journal: Blood (2010)
High Dose Sargramostim (GM-CSF) Combined with IV Plerixafor for the Mobilization of Peripheral Blood Stem Cells (PBSC) From Normal HLA-Matched Allogeneic Sibling Donors Results in Hypercoagulability
Authors: Mark A. Schroeder, Sandra Lopez, Michael P. Rettig, Kathryn Trinkaus, Peter Westervelt, John F. DiPersio
Journal: Blood (2012)